Premium
Single‐Dose Kinetics of Intravenous Vancomycin
Author(s) -
KROGSTAD DONALD J.,
MOELLERING ROBERT C.,
GREENRLATT DAVID J.
Publication year - 1980
Publication title -
the journal of clinical pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1980.tb01696.x
Subject(s) - medicine , infectious disease (medical specialty) , medical school , general hospital , clinical microbiology , hospital medicine , vancomycin , clinical pharmacology , family medicine , disease , pharmacology , staphylococcus aureus , microbiology and biotechnology , medical education , genetics , bacteria , biology
The pharmacokinetic properties of intravenously administered vancomycin were studied in four healthy volunteers. Reversible adverse effects (flushing, tachycardia, pruritus) occurred in two subjects who received high-dose rapid intravenous infusions. Distribution of vancomycin proceeded as a biphasic process in all four subjects. The initial distribution half-life (t1/2 alpha) was less than 8 minutes in all cases, with intermediate half-lives (t1/2 pi) varying from 0.43 to 1.48 hour and elimination half-lives (t1/2 beta) varying from 4.7 to 11.2 hours. Vancomycin clearance was less than creatinine clearance, probably because of serum protein binding, which was determined to be 55 per cent.